We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
TxCell to Present at BIO CEO & Investor Conference 2014
News

TxCell to Present at BIO CEO & Investor Conference 2014

TxCell to Present at BIO CEO & Investor Conference 2014
News

TxCell to Present at BIO CEO & Investor Conference 2014

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "TxCell to Present at BIO CEO & Investor Conference 2014"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

TxCell SA has announced that Damian Marron, CEO, TxCell, will present at BIO CEO & Investor Conference 2014. The conference will take place on February 10 - 11, 2014 in New York City, USA.

An overview of the company, its clinical developments and milestones will be provided.

TxCell’s corporate presentation is scheduled for Tuesday, February 2, 2014 at 10:15 a.m. PT at the Park South of the Waldorf Astoria Hotel, 301 Park Avenue, New York, NY 10022.

The Company will discuss its unique personalized technology platform, ASTrIA. The platform is based on the properties of autologous antigen-specific regulatory T lymphocytes (Ag-Tregs) for treating severe, chronic autoimmune inflammatory diseases.

The review will include the latest clinical data of Ovasave®, TxCell lead product candidate in refractory Crohn’s disease, currently in phase II development. There are 100,000 sufferers of refractory Crohn’s disease in the 7 major markets.

Additional information will be disclosed about the recently announced entry into full development of Col-Treg, TxCell’s second product candidate for the treatment of Autoimmune Uveitis, a rare disease causing blindness. Autoimmune Uveitis causes 10 - 15% of legal blindness in the developed world and 30,000 new cases of blindness per year in the US alone.

Details of the Company’s projects for 2014 will also be provided.

Advertisement